WW INTERNATIONAL, INC. (WW): Results of Operations and Financial Condition
WW INTERNATIONAL, INC. (WW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Weight Watchers Announces Second Quarter 2026 Results Total End of Period Subscribers of 2.5 million; End of Period Clinical Subscribers of 197 thousand, up 55.7% year-over-year Core+ End of Period Subscribers of 541 thousand, up 13.9% year-over-year, reflecting thir
How this was made
The 30-second read
Why it matters
The most tradable elements are the Q2 subscriber and revenue/margin metrics, cash generation, term-loan prepayment reducing interest expense, and the reaffirmed FY 2026 revenue ($620M-$635M) and Adjusted EBITDA ($105M-$115M) guidance.
Market read
Q2 subscriber momentum (Clinical +55.7% YoY, Core+ sequential growth) and reaffirmed FY guidance provide a concrete basis for near-term estimate and sentiment updates.
What to watch
Marketing expense fell sharply (29.5% of revenue vs Q1), which helps margins, but investors may scrutinize whether reduced spend constrains future subscriber acquisition.
Revenue of $162.3 million; Clinical Subscription Revenue of $39.9 million, up 30.4% year-over-year; total end of period subscribers of 2.5 million; and full-year 2026 guidance reaffirmed.
Clinical revenue, Clinical subscribers, Core+ subscribers, ARPU, gross margin and operating cash flow showed favorable reported trends, while Clinical subscribers were flat sequentially after marketing recalibration and the Company described 2026 as a focused transition year. Fresh start accounting also limits comparability with periods on or prior to June 24, 2025.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| RevenueGAAP | $162.3 million | – | – |
| Clinical Subscription RevenueGAAP | $39.9 million | – | 30.4% year-over-year |
| Gross MarginGAAP | 70.3% | – | – |
| Adjusted Gross Marginnon-GAAP | 73.6% | – | – |
| Marketing expenseGAAP | $47.9 million | – | – |
| Marketing expense as a percentage of RevenueGAAP | 29.5% of Revenue | – | – |
| Net IncomeGAAP | $14.1 million | – | – |
| Adjusted EBITDAnon-GAAP | $39.8 million | – | – |
| Total End of Period Subscribersother | 2.5 million | – | – |
| End of Period Clinical Subscribersother | 197 thousand | flat compared to Q1 2026 | 55.7% year-over-year |
| Core+ End of Period Subscribersother | 541 thousand | – | 13.9% year-over-year |
| Monthly Subscription Revenue Per Average Subscriber (ARPU)other | +10.2% year-over-year | – | 10.2% year-over-year |
| Cash and Cash EquivalentsGAAP | $101.5 million | – | – |
| Cash generated by operating activitiesGAAP | $24.3 million | – | – |
| Term loan interest rateother | 10.53% | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| ClinicalEnd of Period Clinical Subscribers grew 55.7% year-over-year, despite lapping significant prior-year growth in Q2 2025 from the Company’s former compounded semaglutide offering. | $39.9 million | – | 30.4% year-over-year |
year ending December 31, 2026 outlook
- Revenue$620 million to $635 million
- NoteAdjusted EBITDA guidance of $105 million to $115 million.
What drove it
- Clinical Subscription Revenue grew 30.4% year-over-year.
- End of Period Clinical Subscribers grew 55.7% year-over-year.
- Core+ subscriber count grew 13.9% year-over-year and posted its third consecutive quarter of sequential growth.
- Monthly Subscription Revenue Per Average Subscriber increased 10.2% year-over-year, driven by the continued mix shift towards Clinical.
- Adjusted Gross Margin of 73.6% reflected continued operational discipline across the Company’s portfolio.
- Marketing expense declined from $92.9 million in Q1 2026 to $47.9 million as the Company moved past peak season and rebalanced investment across its business lines.
Concerns
- End of Period Clinical Subscribers were flat compared to Q1 2026 following a strategic recalibration of Clinical marketing investment after elevated Q1 2026 spend.
- Clinical results lapped significant prior-year growth in Q2 2025 from the Company’s former compounded semaglutide offering.
- Q2 Net Income of $14.1 million reflects higher depreciation and amortization related to Fresh Start Accounting.
- The Company applied fresh start accounting following its emergence from the financial reorganization process on June 24, 2025, and stated that consolidated financial statements after June 24, 2025 are not comparable with statements as of or prior to that date.
What to watch
- Whether Clinical subscriber growth resumes following the recalibration of marketing investment.
- Whether Core+ continues its sequential subscriber growth beyond the third consecutive quarter reported.
- Execution against reaffirmed full-year 2026 Revenue guidance of $620 million to $635 million and Adjusted EBITDA guidance of $105 million to $115 million.
- Further cash generation and term-loan principal reduction following the $36.8 million Q2 cash prepayment.
Balance sheet and cash flow
- Cash and Cash Equivalents balance as of June 30, 2026 was $101.5 million.
- Operating activities generated $24.3 million of cash in Q2 2026.
- In Q2 2026, the Company prepaid $36.8 million in cash to reduce the principal amount of its outstanding term loan.
- In June 2026, $26.8 million in aggregate principal amount of prepayment from the annual cash sweep.
- In May 2026, $10.0 million as part of the voluntary solicitation, which was fully subscribed at 68.5% of par.
- The Company reduced the aggregate principal amount of its outstanding term loan by $41.4 million and reduced its annualized interest expense by approximately $4 million.
- The interest rate in effect for the term loan as of June 30, 2026 was 10.53%.
Analysis
WW International reported Q2 revenue of $162.3 million, with Clinical Subscription Revenue of $39.9 million, up 30.4% year-over-year. The Clinical business added reported scale, with 197 thousand end-of-period Clinical Subscribers, up 55.7% year-over-year. However, Clinical subscribers were flat compared to Q1 2026 as the Company recalibrated Clinical marketing investment after elevated Q1 spending.
The Behavioral business showed stabilization indicators. Core+ ended the quarter with 541 thousand subscribers, up 13.9% from Q2 2025 and marking the third consecutive quarter of sequential growth in the higher-value Behavioral tier. Monthly Subscription Revenue Per Average Subscriber increased 10.2% year-over-year, which the Company attributed to continued mix shift toward Clinical.
Profitability and cash generation were positive in the reported period. Gross Margin was 70.3% and Adjusted Gross Margin was 73.6%, which management said reflected operational discipline. Marketing expense was $47.9 million, or 29.5% of Revenue, down from $92.9 million in Q1 2026 as peak season ended and investment was rebalanced. Net Income was $14.1 million, reflecting higher depreciation and amortization related to Fresh Start Accounting, while Adjusted EBITDA was $39.8 million.
Liquidity actions were material. Cash and Cash Equivalents were $101.5 million as of June 30, 2026, and operating activities generated $24.3 million of cash in Q2. The Company prepaid $36.8 million in cash against its term loan and said the related actions reduced aggregate term-loan principal by $41.4 million and annualized interest expense by approximately $4 million. The term-loan interest rate was 10.53% as of June 30, 2026.
Management reaffirmed full-year 2026 Revenue guidance of $620 million to $635 million and Adjusted EBITDA guidance of $105 million to $115 million. The central reported operating indicators are the durability of Clinical growth after marketing normalization, continued Core+ subscriber growth, and maintenance of gross margin and operating cash flow. Comparisons with periods on or before June 24, 2025 require caution because the Company applied fresh start accounting after emerging from its financial reorganization process.
Management, verbatim
We view 2026 as a year of focused transition for Weight Watchers, and our Q2 results reflect that work taking hold across the business.
Jon Volkmann, Chief Operations Officer and member of the Company’s Interim Office of the Chief Executive
We are reaffirming our full-year 2026 Revenue and Adjusted EBITDA guidance. With a business that remains cash accretive and generated positive operating cash flow in Q2, we have confidence in our ability to continue building momentum into 2027 and beyond.
Felicia DellaFortuna, Chief Financial Officer and member of the Company’s Interim Office of the Chief Executive
Not in the filing
stated, not guessed- Prior-year and prior-quarter total Revenue
- Total Revenue year-over-year and quarter-over-quarter change
- Behavioral Subscription Revenue
- Other Revenue
- Behavioral subscriber count
- Prior-year and prior-quarter Gross Margin
- Gross profit
- Operating income
- Operating expenses other than marketing expense
- Selling, general and administrative expense
- Product development expense
- GAAP and non-GAAP diluted earnings per share
- Prior-year and prior-quarter Net Income
- Net Income year-over-year and quarter-over-quarter change
- Prior-year and prior-quarter Adjusted EBITDA
- Adjusted EBITDA year-over-year and quarter-over-quarter change
- Free cash flow
- Total debt or outstanding term-loan principal balance
- Share repurchases
- Dividends
- Forward gross-margin guidance
- Forward operating-expense guidance
- Forward tax-rate guidance
- Previous outlook section for guidance comparison
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
WW filed an 8-K for Q2 2026 results (ended June 30, 2026) under Item 2.02, including an earnings press release and shareholder letter.
Ticker impact
WW reported Q2 2026 results with 2.5M end-of-period subscribers, Clinical subscribers up 55.7% YoY, and reaffirmed full-year revenue and Adjusted EBITDA guidance.
Moderate positive bias for the next session as investors weigh subscriber momentum and margin/EBITDA guidance reaffirmation.
Key metrics (Clinical growth, Core+ sequential growth, ARPU up 10.2% YoY, gross margin 70.3%) and cash generation are supportive, while the guidance is reaffirmed rather than raised, limiting upside surprise.
Market effects
Adds incremental evidence on Weight Watchers' shift toward higher-value Behavioral (Core+) and Clinical mix, relevant to consumer health and digital weight-management sentiment.
Primarily US-listed equity impact; limited direct regional spillover beyond investor sentiment for health subscription models.
Global subscriber and clinical growth signals can influence broader appetite for science-backed weight-management platforms.
Counterpoint
Clinical subscriber growth is partly influenced by lapping prior-year semaglutide-related growth and marketing recalibration, so durability of the mix shift may be questioned.
Key entities
- public_companyWW International, Inc.
Weight Watchers, Nasdaq: WW, reporting Q2 2026 results and reaffirming full-year 2026 guidance.
- executiveJon Volkmann
Chief Operations Officer, quoted on Q2 results and Core+ momentum.
- executiveFelicia DellaFortuna
Chief Financial Officer, quoted on Clinical growth, marketing recalibration, and guidance reaffirmation.
